Inpharma 1356 - 21 Sep 2002

■ Risperidone plus fluvoxamine is a novel strategyfor the treatment of major depression, according toresearchers from the US and Japan. In this study, 36patients with major depressive disorder received oralfluvoxamine [‘Luvox’] 75–150 mg/day, and oralrisperidone [‘Risperdal’] 0.5–1 mg/day, for 6 weeks. Atstudy end, 76% of the 30 evaluable subjects achieveda ≥ 75% reduction from baseline in the mean HamiltonRating Scale for Depression (HAM-D) score; 17%achieved a reduction of 50%–74%. Approximately 60%of the patients achieved a ≥ 50% improvement in theHAM-D score within the first 2 weeks of treatment.The combination of fluvoxamine and risperidone waswell tolerated.Hirose S, et al. An open pilot study combining risperidone and a selectiveserotonin reuptake inhibitor as initial antidepressant therapy. Journal ofClinical Psychiatry 63: 733-736, Aug 2002 800917410

1

Inpharma 21 Sep 2002 No. 13561173-8324/10/1356-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved